Clinical Trials

MISSION of clinical trials conducted at Clinical Research Center in Hawaii is:

Our HOPE is that it can meet an unmet need for

Research Therapies are FREE to qualified patients and some may also offer FREE neighbor island travel ALL patients continue to follow up with their primary neurologists & primary care physicians while in trial

Conditions	Indications	Study Name	Treatment/MOA	NIH Website	Who Qualifies
Alzheimer’s Memory	MCI, Mild Mod AD	PRESENCE AD	PO LY3154207 (Mevidalen) D1 Receptors	NCT06538116	MMSE 13-24
Alzheimer’s Memory	MCI, Mild AD	BRAINSHUTTLE	IV RO7126209 (Trontinemab)	NCT04639050	MMSE 22-30
Alzheimer’s Memory	MCI, Mild AD		PO Buntanetap (Neuroprotective)		MMSE 21-28
Alzheimer’s Memory	MCI, Mild AD		IV VHB937 (TREM2 Activator)		CDR 0.5-1
Alzheimer’s Memory	AD, Agitation		PO NMRA-323511 V1a Receptor	NCT06546995	MMSE 5-24
Parkinson’s	Early PD	LUMA	PO BIIB1222 - LRRK2 - DMT	NCT05348785	PD within 2 years
Parkinson’s	PD with Motor Fluctuations		PO Lu AF28996 – D1 D2 Agonist	NCT04291859	> 1.5 hr OFF
Epilepsy	Focal Seizure	RISE 2	PO BHV-7000 VG Potassium channel	NCT06132893	> 4 seizures/month
Epilepsy	Focal Seizure	X-TOLE2	PO XEN1101 Novel Potassium channel	NCT05614063	> 4 seizures/month
Epilepsy	Primary Generalized	X-TOLE3	PO XEN1101 Novel Potassium channel	NCT05667142	3 PGTC in 8 weeks
Epilepsy	Focal or Generalized	STARS	Inhaled Abortive EP0162 Staccato Alprazolam	NCT05077904	Seizures
MS Neuroimmunology	RRMS		IV ABP 692 vs Ocrevus		EDSS ≤ 5.5 ≥ 2 relapse ≤ 2 years
Neuromuscular	CIDP	HYbISCUE	IV HyQvia	NCT06538064	CIDP 2021 Guidelines
Neuromuscular	Myasthenia Gravis	APPRAISE	PO LNP023 (Iptacopan)	NCT06517758	MGFA Class II-IV
Neuromuscular	Spasticity	DIRECTION	IM Dysport Abobotulinumtoxin A	NCT04936542	Spasticity > 3 mths
Pain	Migraine	PIONEER	PO LAHV/LAHW/Lasmiditan	NCT04396236	Migraine > 6 mths
Pain	Migraine Menstrual	MOSAIC	PO Ubrogepant		Migraine > 12 months 2 out of 3 are menstrual
Psychiatric Neuro	Post Partum Dépression	RECONNECT	SQ RE 104	NCT06342310	DSM5 Post PD
Psychiatric Neuro	Adjustment Disorder in ALS, MS, Parkinson’s	ADCO	SQ RE 104		AjD > 4 weeks
Rare Neuro Diseases	Dentatorubral-Pallidoluysian Atrophy			Intrathecal nL-ATN-002 ASO Therapy	FDA IND 173123-Open label single center single patient

Kore Kai Liow, MD, FACP, FAAN

Principal Investigator, Clinical Research Center
Hawaii Pacific Neuroscience
Clinical Professor, Dept. of Medicine (Neurology),
Graduate Faculty, Clinical & Translational Research
University of Hawai`i John Burns School of Medicine